亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

U3-1402, a Novel HER3-Targeting Antibody–Drug Conjugate, for the Treatment of Colorectal Cancer

抗体-药物偶联物 结合 结直肠癌 癌症研究 医学 药品 癌症 药理学 抗体 单克隆抗体 生物 计算生物学 内科学 免疫学 数学 数学分析
作者
Shigehiro Koganemaru,Yasutoshi Kuboki,Yoshikatsu Koga,Takashi Kojima,Mayumi Yamauchi,Naoyuki Maeda,Takashi Kagari,Kenji Hirotani,Masahiro Yasunaga,Yasuhiro Matsumura,Toshihiko Doi
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:18 (11): 2043-2050 被引量:95
标识
DOI:10.1158/1535-7163.mct-19-0452
摘要

Abstract HER3 is overexpressed in several cancers, including colorectal cancer. Although therapies with anti-HER3 antibodies have been investigated, significant clinical benefits have not been reported. U3-1402 is a novel HER3-antibody–drug conjugate (ADC) composed of the HER3 antibody patritumab and a novel topoisomerase I inhibitor, DX-8951 derivative (DXd). The sensitivity of DXd was evaluated by a growth inhibition assay. The antitumor activity of U3-1402 was evaluated in a murine xenograft model in which its effects on cells, with a range of HER3 expression levels, were compared with those of patritumab alone, irinotecan, control-ADC, and saline. In the growth inhibition assay, all colorectal cancer cell lines were sensitive to DXd. In the tumor xenograft model, significant tumor regression with U3-1402 was observed both in the DiFi cell line (high HER3 expression; KRAS wild type) and in SW620 (high HER3 expression; KRAS mutation), but no treatment effect was observed in Colo320DM (low HER3 expression). Notably, SW620 tumor growth was significantly suppressed with U3-1402 compared with the saline-treated group (P < 0.001) and showed greater activity compared with the irinotecan group. By contrast, patritumab alone, control-ADC, and saline did not significantly differ in tumor growth inhibition. The antitumor activity of U3-1402 was dependent on HER3 expression level, but not on KRAS mutation status. These results support further investigation of development strategies for U3-1402 in patients with HER3-expressing colorectal cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘻嘻哈哈的应助被踏实香氛采纳,获得10
1秒前
2秒前
英姑的应助被小医采纳,获得10
4秒前
yl完成签到,获得积分20
5秒前
烟花的应助被磊4165564采纳,获得10
8秒前
12秒前
15秒前
15秒前
ui24完成签到 ,获得积分10
16秒前
16秒前
18秒前
18秒前
19秒前
磊4165564发布了新的文献求助10
22秒前
23秒前
小医发布了新的文献求助10
24秒前
25秒前
25秒前
26秒前
26秒前
27秒前
28秒前
SciGPT的应助被渡增越采纳,获得10
30秒前
30秒前
富婆丹完成签到 ,获得积分10
31秒前
周宇飞完成签到 ,获得积分10
32秒前
欢喜的诗珊完成签到,获得积分10
32秒前
33秒前
ccc完成签到 ,获得积分10
35秒前
肉包子发布了新的文献求助10
35秒前
醉酒的帅哥完成签到,获得积分10
36秒前
小林的火恐龙完成签到 ,获得积分10
39秒前
汤圆发布了新的文献求助10
40秒前
40秒前
永和完成签到,获得积分10
40秒前
41秒前
土土桔子糖完成签到 ,获得积分10
44秒前
椰子云发布了新的文献求助10
45秒前
mmhk发布了新的文献求助10
45秒前
49秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554333
关于积分的说明 21718908
捐赠科研通 7748056
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551841
邀请新用户注册赠送积分活动 2471242